Ascidian Therapeutics

We’re thrilled our President and CEO, Michael Ehlers, is taking on a new role as an Entrepreneur Partner at MPM BioImpact! He’ll continue to lead us here at Ascidian, as he supports innovation across the biotech ecosystem. Congratulations, Mike!  https://lnkd.in/ewZGKaxn

Missed the ‘Journey Through Vision Loss’ event at The Carroll Center for the Blind? You can still catch our #TeamAscidian presentation, 'Hope on the Horizon: ACDN-01 for Stargardt Disease.' Special thanks to Robert Bell, Alia Rashid, and Amber Trzeciak for their invaluable insights on:   🔆 Clinical Trials  🔆 #RNAExonEditing  🔆 ACDN-01, our lead program targeting #StargardtDisease 🔆 The #STELLARClinicalTrial   Watch the recording 👉 https://lnkd.in/eA3shJPV and then learn more about ACDN-01 and the STELLAR trial here: https://bit.ly/4cmDjhO

#TeamAscidian is closing out #BlindnessAwarenessMonth by gearing up for the last segment of the 'Journey Through Vision Loss' event at The Carroll Center for the Blind this Saturday, November 2. Our own Robert Bell, Alia Rashid and Amber Trzeciak will be covering 'Hope on the Horizon: ACDN-01 for Stargardt Disease' by diving into: 💠 The ins and outs of clinical trials 👨🔬 💠 All things #RNAExonEditing ✨ 💠 ACDN-01, our lead program targeting #StargardtDisease 🚀 🔹 How it works 🔹 The study design and updates about our #STELLARClinicalTrial The event will be recorded, so stay tuned! In the meantime, learn more about ACDN-01 and the STELLAR trial here: https://bit.ly/4cmDjhO and check out the event details below 👇

RNA editing is receiving global attention. In this excellent Nikkei piece, Ascidian’s Daniel Rosan explains how Ascidian was "able to reach clinical trials in a shorter period of time and with less investment than any other preceding gene editing technology” for our #RNAExonEditing lead program. In Japanese: https://lnkd.in/dS4MDywS English translation: https://lnkd.in/dpswMM34

Gwendolyn Wu and Ben Fidler of BioPharma Dive provide a state-of-play in the cutting-edge field of RNA editing. As our own Michael Ehlers explains, “It has all the features of a technology that could leapfrog other editing technologies.” Explore the evolution of RNA editing, the field’s latest breakthroughs, and how Ascidian's pioneering #RNAExonEditiors expand the possibilities of RNA medicines — making it possible to target “diseases caused by many different mutations rather than just one” 👉 https://lnkd.in/dnrJzgAi

Bradford Manning is the real master, and we are here for it! Thank you, Brad, for inviting us to take part in your impressive master class on #StargardtDisease – you’ve created something really special with this curriculum, and we’re grateful to be a part of it. If you haven’t already checked it out, #BlindnessAwarenessMonth is the perfect time to explore the class: https://bit.ly/3yB9trX #ShareYourVoice

For #WorldSightDay, we're celebrating Lucia and Sarafina, the “Stargardt Sisters” – who share an incredible bond in addition to a #StargardtDisease diagnosis. We’re immensely grateful to their mom, Sarah, for Zooming in with #TeamAscidian to share their story. It was a true pleasure to have you with us, Sarah. Hearing about Lucia, Sarafina, and your whole family of eight ignites our passion and reinforces why we do what we do. Thank you! Learn more about the ‘Stargardt Sisters’ and their family via the Foundation Fighting Blindness here: https://lnkd.in/eK4hA72G #ShareYourVision

Congratulations to Ascidian President and CEO, Michael Ehlers, MD, PhD, for being named to the #PharmaVoice100, recognizing individuals who are a driving force in the industry. We’re proud to have Mike on #TeamAscidian.👏 Check out Mike's profile here: https://lnkd.in/ebCt4CFa and the full PharmaVoice article here: https://lnkd.in/ez3F-mj6

#TeamAscidian is thrilled to be at the Alliance for Regenerative Medicine’s 2024 Cell & Gene Meeting on the Mesa in Arizona. 🌵 Join us Wednesday morning as our Chief Financial and Business Officer, Daniel Rosan, takes the podium to share the latest on all things #RNAExonEditing. Don't miss it—see you there! #CGMesa24

#TeamAscidian had a whale of a time at last night’s #Fierce15 Award Ceremony! 🏆🎊 We’re on a roll – and more motivated than ever to bring #RNAExonEditing to patients. Thank you again, Fierce Biotech, for the recognition. Read more here: https://lnkd.in/eaUgfbmc Rebecca Willumson, Gabrielle Masson